AMSTERDAM, April 7, 2026 /PRNewswire/ — OCI Global (Euronext: OCI), (“OCI”) provides the following update regarding its shareholding in Methanex Corporation.
Since OCI’s H2 2025 earnings announcement on 16 March 2026, trading volumes in Methanex shares have increased significantly, which may provide additional flexibility with respect to potential future disposals. In light of these evolving circumstances, among other factors, the Board has authorized management to consider selling Methanex shares from time to time, as and when it determines appropriate.
About OCI Global
Learn more about OCI at www.oci-global.com. You can also follow OCI on LinkedIn.
Contact Details:
Sarah Rajani CFA,
Global Vice President Investor Relations & Communications,
Email: sarah.rajani@oci-global.com
View original content:https://www.prnewswire.co.uk/news-releases/oci-global-statement-on-methanex-shareholding-302735441.html
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…
June 05, 2026 19:30 ET | Source: Oban BioPharma, Inc. STAMFORD, Conn., June 05, 2026…
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…
June 05, 2026 20:13 ET | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…
Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and…